Erlotinib and gefitinib, two epidermal growth factor receptor (EGFR) and tyrosine kinase inhibitors, have also been tested in patients with endometrial cancer, as EGFR is overexpressed in 40–46% of Type I endometrial carcinoma cases, and in 34% of Type II endometrial carcinomas [11]. The gene discussed is EGFR; the disease is endometrial cancer.